INVO Bioscience, Inc. (INVO) Q1 2022 Earnings Conference Call May 16, 2022 4:30 PM ET
Company Participants
Robert Blum - Lytham Partners, LLC, IR
Steven Shum - CEO
Michael Campbell - COO and VP, Business Development
Andrea Goren - CFO
Conference Call Participants
John Heerdink - Vista Partners
Operator
Good day, and welcome to the INVO Bioscience First Quarter 2022 Financial Results Conference Call. Today all participants will be in a listen-only mode. [Operator Instructions]. After today's presentation, there will be an opportunity to ask questions. [Operator Instructions]. Please, note that today’s event is being recorded.
I would now like to turn the conference over to Robert Blum with Lytham Partners. Please, go ahead sir.
Robert Blum
All right. Thank you very much, Chris. Good afternoon, everyone. And thank you all for joining us for today’s INVO Bioscience's first quarter 2022 financial results conference call. Joining us on today's call is INVO Bioscience's CEO, Steven Shum, the Company's Chief Operating Officer and VP of Business Development, Mike Campbell, and Andrea Goren, the Company's Chief Financial Officer. At the conclusion of today's prepared remarks, we will open the call for a question-and-answer session.
Before we begin with the event, we submit for the record the following statement. Certain matters discussed on this conference call by the management of INVO Bioscience, may be forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 as amended, Section 21E of the Securities Exchange Act of 1934 as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
All statements regarding the Company's expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words
- Read more current IVF analysis and news
- View all earnings call transcripts